Adial Pharmaceuticals, Inc.: 10-K filed 2020-03-20

Name: Adial Pharmaceuticals, Inc.: 10-K filed 2020-03-20
Creator: Adial Pharmaceuticals, Inc.

What Adial Pharmaceuticals, Inc. reported in its annual report filed 2020-03-20 (fiscal FY 2019): 26 published measures, 52 facts as tagged in accession 0001213900-20-007020.

This filing

Form: 10-K (annual report)
Filed: 2020-03-20
Fiscal period: fiscal FY 2019
Accession: 0001213900-20-007020 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Adial Pharmaceuticals, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2019-12-31	7,679,637	USD
At 2018-12-31	4,699,285	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit
At 2019-12-31	7,140,586	USD
At 2018-12-31	4,441,311	USD
At 2017-12-31	-997,553	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit
At 2019-12-31	6,777,052	USD
At 2018-12-31	3,869,043	USD
At 2017-12-31	18,248	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2019-01-01 to 2019-12-31	-8,591,429	USD	365
2018-01-01 to 2018-12-31	-11,631,378	USD	365

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2019-01-01 to 2019-12-31	-6,338,614	USD	365
2018-01-01 to 2018-12-31	-2,498,387	USD	365

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2019-01-01 to 2019-12-31	9,246,623	USD	365
2018-01-01 to 2018-12-31	6,349,182	USD	365

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2019-12-31	-20,626,799	USD
At 2018-12-31	-12,035,370	USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2019-01-01 to 2019-12-31	1,602,318	USD	365
2018-01-01 to 2018-12-31	5,368,354	USD	365

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2019-01-01 to 2019-12-31	-8,244,900	USD	365
2018-01-01 to 2018-12-31	-6,987,222	USD	365

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2019-12-31	7,673,467	USD
At 2018-12-31	4,692,550	USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2019-12-31	539,051	USD
At 2018-12-31	257,974	USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2019-12-31	190,204	USD
At 2018-12-31	99,671	USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

Period	Value	Unit	Days
At 2019-12-31	6,170	USD
At 2018-12-31	6,735	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2019-01-01 to 2019-12-31	8,244,900	USD	365
2018-01-01 to 2018-12-31	6,987,222	USD	365

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2019-01-01 to 2019-12-31	3,965,543	USD	365
2018-01-01 to 2018-12-31	368,459	USD	365

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2019-12-31	10,368,352	shares
At 2018-12-31	6,862,499	shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2019-12-31	27,757,017	USD
At 2018-12-31	16,469,818	USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

Period	Value	Unit	Days
At 2019-12-31	6,170	USD
At 2018-12-31	6,735	USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

Period	Value	Unit	Days
At 2019-12-31	348,847	USD
At 2018-12-31	158,303	USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

Period	Value	Unit	Days
At 2019-12-31	359,499	USD
At 2018-12-31	317,547	USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

Period	Value	Unit	Days
2019-01-01 to 2019-12-31	-8,591,429	USD	365
2018-01-01 to 2018-12-31	-11,631,378	USD	365

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

Period	Value	Unit	Days
2019-01-01 to 2019-12-31	-8,591,429	USD	365

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2019-01-01 to 2019-12-31	4,279,357	USD	365
2018-01-01 to 2018-12-31	6,618,763	USD	365

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

Period	Value	Unit	Days
2019-01-01 to 2019-12-31	565	USD	365
2018-01-01 to 2018-12-31	563	USD	365

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

Period	Value	Unit	Days
2019-01-01 to 2019-12-31	-346,529	USD	365
2018-01-01 to 2018-12-31	-4,644,156	USD	365

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

Period	Value	Unit	Days
2018-01-01 to 2018-12-31	38,160	USD	365

Inspect the source

Entity: Adial Pharmaceuticals, Inc. / CIK 0001513525
Captured: 2026-09-20T09:13:16.139Z
SEC response SHA-256: a18f3033034427d32ef6db390e21f05d7acd23d932b720bc7458a3fbeee3e90d

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001513525.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))